Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
AgomAb Therapeutics from Antwerpen, company number BE0674527310, closed financial year 2025 with a result of € -9.6 million after tax. Compared with financial year 2024, the result moved from € -11.7 million to € -9.6 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ 244.1 million
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -9.6 million
▲ 18 % less loss than in 2024
Profit after tax over the fiscal year.
€ 73 million
▲ 195% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -55.6 million.
People and assets in 2025
52
▲ 11.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 10.6 million
▲ 25% vs 2024
€ 203,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 189,803
▲ 16% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3.6 million
▲ 57% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 108 days on average.
€ 2.2 million
▲ 19% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 993,210 | € 1,477,010 | € 3,962,010 | - | |
| Profit after taxes | € -9,396,576 | € -8,440,501 | € -11,716,884 | € -9,622,983 | ▲ € 2.1 million |
| Equity | € 96,919,958 | € 183,349,854 | € 253,687,197 | € 244,064,213 | ▼ 4% |
| Total debts | € 4,369,871 | € 5,381,503 | € 4,975,067 | € 7,266,283 | ▲ 46% |
| Cash | € 26,867,915 | € 121,905,179 | € 24,771,606 | € 73,005,957 | ▲ 195% |
| Retained profit | € -25,860,807 | € -34,301,308 | € -46,018,192 | € -55,641,175 | ▼ € 9.6 million |
| Balance sheet total | € 101,289,830 | € 188,731,357 | € 258,662,264 | € 251,330,496 | ▼ 3% |
| Employees (FTE) | 10.1 | 19.4 | 40.9 | 52 | ▲ 11.1 |
Key figures of AgomAb Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AgomAb Therapeutics?
What happened at AgomAb Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Colin Bond stepped down as director. NBB
- David Epstein stepped down as director. NBB
- Angelika Martha Jahreis stepped down as director. NBB
- Felice Verduyn - van Weegen stepped down as director. NBB
- Tim Knotnerus stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 9.6 million. Source: NBB ↗
- Ohad Hammer stepped down as director. NBB
- Xiaoming Fang stepped down as director. NBB
In short
From € 9.4 million loss in 2022 to € 9.6 million loss in 2025.
On average € 96,900 of value added per employee in 2024.
Pays suppliers within 108 days on average.
A new publication or filing at AgomAb Therapeutics? We notify you, reason included.
Follow AgomAb TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 100% of Agomab US Inc. and 100% of Agomab Spain SLU itself.
Directors
According to the 2025 annual accounts
Angelika Martha Jahreis
Director
since 2023 · until 2029
Tim Knotnerus
Managing director
since 2021 · until 2027
Ohad Hammer
Director
since 2019 · until 2026
Felice Verduyn - van Weegen
Director
since 2023 · until 2029
Colin Bond
Director
since 2024 · until 2030
Xiaoming Fang
Director
since 2023 · until 2026
David Epstein
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Posthoflei 1 box 6
2600 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0674.527.310
- VAT number
- BE 0674.527.310
- Registered office
- Posthoflei 1 bus 6, 2600 Antwerpen
- Names & denominations
- AgomAb Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 April 2017
- Peppol
- Active · Active since 5 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige technische testen en toetsen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied